BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
rs2230926
,
IGF1
,
T cell differentiation
,
Inflammatory disorder
,
Lymphocyte
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
cep 1
Summary
General Info
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
Anaplastic Large Cell Lymphoma and ALK-mediated signaling inhibition by RNAi and compounds
Anaplastic Large Cell Lymphoma SUDHL-1 cells treated with ALK inhibitor CEP-14083
Explore Curated Studies Results
Literature
Most Relevant Literature
Neuronal IL-17 controls Caenorhabditis elegans developmental diapause through CEP-1/p53.
cep-1 mediated the mitohormesis effect of Shengmai formula in regulating Caenorhabditis elegans life…
Histone Demethylase AMX-1 Regulates Fertility in a p53/CEP-1 Dependent Manner.
3,3'-Diindolylmethane Supplementation Maintains Oocyte Quality by Reducing Oxidative Stress and CEP-…
Caenorhabditis elegans NHR-14/HNF4α regulates DNA damage-induced apoptosis through cooperating with …
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Phase 1 Study of CEP-37250/KHK2804 in Subjects With Advanced Solid Tumors
A 48-Week (24-Week Baseline Followed by a 24-Week Treatment) Phase II Pilot Study of the Tolerabilit…
Safety and Efficacy Study of CEP-1347 in the Treatment of Parkinson's Disease
Delanzomib (CEP-18770) in Combination With Lenalidomide and Dexamethasone in Relapsed or Refractory …
Study to Determine the Maximum Tolerated Dose of the PARP Inhibitor CEP-9722 in Patients With Solid …
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ